164 related articles for article (PubMed ID: 34053585)
1. Theranostics in Neuroblastoma.
Rafael MS; Cohen-Gogo S; Irwin MS; Vali R; Shammas A; Morgenstern DA
PET Clin; 2021 Jul; 16(3):419-427. PubMed ID: 34053585
[TBL] [Abstract][Full Text] [Related]
2. 18F-FDG PET/CT and 123I-metaiodobenzylguanidine imaging in high-risk neuroblastoma: diagnostic comparison and survival analysis.
Papathanasiou ND; Gaze MN; Sullivan K; Aldridge M; Waddington W; Almuhaideb A; Bomanji JB
J Nucl Med; 2011 Apr; 52(4):519-25. PubMed ID: 21421719
[TBL] [Abstract][Full Text] [Related]
3. MIBG (metaiodobenzylguanidine) theranostics in pediatric and adult malignancies.
Agrawal A; Rangarajan V; Shah S; Puranik A; Purandare N
Br J Radiol; 2018 Nov; 91(1091):20180103. PubMed ID: 30048149
[TBL] [Abstract][Full Text] [Related]
4. Current Status and Future Perspective on Molecular Imaging and Treatment of Neuroblastoma.
Feng L; Li S; Wang C; Yang J
Semin Nucl Med; 2023 Jul; 53(4):517-529. PubMed ID: 36682980
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma.
Messina JA; Cheng SC; Franc BL; Charron M; Shulkin B; To B; Maris JM; Yanik G; Hawkins RA; Matthay KK
Pediatr Blood Cancer; 2006 Dec; 47(7):865-74. PubMed ID: 16444675
[TBL] [Abstract][Full Text] [Related]
6. Nuclear medicine procedures and neuroblastoma in childhood. Their value in the diagnosis, staging and assessment of response to therapy.
Boubaker A; Bischof Delaloye A
Q J Nucl Med; 2003 Mar; 47(1):31-40. PubMed ID: 12714952
[TBL] [Abstract][Full Text] [Related]
7. 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma.
Sharp SE; Shulkin BL; Gelfand MJ; Salisbury S; Furman WL
J Nucl Med; 2009 Aug; 50(8):1237-43. PubMed ID: 19617326
[TBL] [Abstract][Full Text] [Related]
8. 124I-MIBG: a new promising positron-emitting radiopharmaceutical for the evaluation of neuroblastoma.
Cistaro A; Quartuccio N; Caobelli F; Piccardo A; Paratore R; Coppolino P; Sperandeo A; Arnone G; Ficola U
Nucl Med Rev Cent East Eur; 2015; 18(2):102-6. PubMed ID: 26315872
[TBL] [Abstract][Full Text] [Related]
9. Follow-up in neuroblastoma: comparison of metaiodobenzylguanidine and a chimeric anti-GD2 antibody for detection of tumor relapse and therapy response.
Reuland P; Geiger L; Thelen MH; Handgretinger R; Haase B; Müller-Schauenburg W; Niethammer D; Bares R
J Pediatr Hematol Oncol; 2001 Oct; 23(7):437-42. PubMed ID: 11878578
[TBL] [Abstract][Full Text] [Related]
10. Pediatrics: diagnosis of neuroblastoma.
Sharp SE; Gelfand MJ; Shulkin BL
Semin Nucl Med; 2011 Sep; 41(5):345-53. PubMed ID: 21803184
[TBL] [Abstract][Full Text] [Related]
11. Different outcomes for relapsed versus refractory neuroblastoma after therapy with (131)I-metaiodobenzylguanidine ((131)I-MIBG).
Zhou MJ; Doral MY; DuBois SG; Villablanca JG; Yanik GA; Matthay KK
Eur J Cancer; 2015 Nov; 51(16):2465-72. PubMed ID: 26254811
[TBL] [Abstract][Full Text] [Related]
12. [Metaiodobenzylguanidine scintigraphy in the diagnosis and followup of neuroblastoma. Apropos of 16 cases].
Hammami H; Hassine L; Mhiri A; Sellem A; Oubich F; Gharssallah L; Barsaoui S; Ben Brahim H
Tunis Med; 2007 May; 85(5):413-6. PubMed ID: 17657930
[TBL] [Abstract][Full Text] [Related]
13. Neuroblastoma and other neuroendocrine tumors.
Howman-Giles R; Shaw PJ; Uren RF; Chung DK
Semin Nucl Med; 2007 Jul; 37(4):286-302. PubMed ID: 17544628
[TBL] [Abstract][Full Text] [Related]
14. Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma.
DuBois SG; Matthay KK
Nucl Med Biol; 2008 Aug; 35 Suppl 1(Suppl 1):S35-48. PubMed ID: 18707633
[TBL] [Abstract][Full Text] [Related]
15. [Radio iodized metaiodobenzylguanidine (MIBG) in the treatment of neuroblastoma: modalities and indications].
Défachelles AS; Cougnenc O; Carpentier P
Bull Cancer; 2011 May; 98(5):559-69. PubMed ID: 21609890
[TBL] [Abstract][Full Text] [Related]
16. Guidelines on nuclear medicine imaging in neuroblastoma.
Bar-Sever Z; Biassoni L; Shulkin B; Kong G; Hofman MS; Lopci E; Manea I; Koziorowski J; Castellani R; Boubaker A; Lambert B; Pfluger T; Nadel H; Sharp S; Giammarile F
Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):2009-2024. PubMed ID: 29938300
[TBL] [Abstract][Full Text] [Related]
17. Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients.
Kushner BH; Yeung HW; Larson SM; Kramer K; Cheung NK
J Clin Oncol; 2001 Jul; 19(14):3397-405. PubMed ID: 11454888
[TBL] [Abstract][Full Text] [Related]
18. Current concepts on the diagnostic use of MIBG in children.
Shulkin BL; Shapiro B
J Nucl Med; 1998 Apr; 39(4):679-88. PubMed ID: 9544682
[TBL] [Abstract][Full Text] [Related]
19. Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy.
Kushner BH; Yeh SD; Kramer K; Larson SM; Cheung NK
J Clin Oncol; 2003 Mar; 21(6):1082-6. PubMed ID: 12637474
[TBL] [Abstract][Full Text] [Related]
20. Clinical impact and prognostic value of metaiodobenzylguanidine imaging in children with metastatic neuroblastoma.
Perel Y; Conway J; Kletzel M; Goldman J; Weiss S; Feyler A; Cohn SL
J Pediatr Hematol Oncol; 1999; 21(1):13-8. PubMed ID: 10029806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
